- The Wilson's Disease Treatment market is estimated to be valued at US$ 560.2 Mn or Mn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Wilson's disease is a rare genetic disorder that causes copper to accumulate in organs such as the liver and brain. The main treatment options include oral supplements to remove excess copper from the body such as penicillamine and trientine. These supplements help excrete copper through urine and prevent further buildup. Zinc acetate is also used to limit copper absorption from diet.
Market Dynamics:
Rising awareness about Wilson's disease is expected to drive the market growth over the forecast period. Growing patient population and initiatives by non-profit organizations to spread information about symptoms and treatment of Wilson's disease is raising awareness. Moreover, ongoing research and new product launches are also boosting the market growth. For instance, in January 2019, Kadmon Holdings, Inc. announced positive initial data from ongoing clinical study of KD025, an oral ROCK2 inhibitor for treating Wilson's disease. The data demonstrated potential of KD025 to control copper levels in Wilson's disease patients. Such pipeline developments are fueling the market growth.
SWOT Analysis
Strengths: The Wilson's Disease Treatment Market has strong growth potential due to rising disease prevalence. Development of new drugs provides improved treatment effectiveness. Government support through funding and regulations encourage market growth.
Weaknesses: High costs associated with drug development and clinical trials hinders new market entrants. Lack of awareness about Wilson's disease in developing nations limits scope for diagnosis and treatment.
Opportunities: Favorable reimbursement policies for orphan drugs boost adoption. Expanding healthcare infrastructure in emerging nations opens new avenues.
Threats: Stiff competition from substitute treatments poses challenges. Stringent drug approval procedures increase time to market entry.
Key Takeaways
The global Wilson’s Disease Treatment market is expected to witness high growth, exhibiting CAGR of 6.3% over the forecast period, due to increasing disease prevalence and government initiatives to spread awareness. According to statistics, over 5000 new cases are reported annually worldwide.
Regional analysis - North America dominated the market with more than 30% share in 2023 owing to strong healthcare infrastructure and early new product adoption. Asia Pacific is poised to grow at 7.2% CAGR during the forecast period. Countries like India, China, and Japan are major hubs for generic drug manufacturing as well as presence of patient populationbase.
Key players operating in the Wilson’s Disease Treatment market are Valeant Pharmaceuticals International, Inc., Noblepharma Co., Ltd., Wilson Therapeutics AB, Kadmon Holdings, Inc., Merck Co., Inc., VHB Life Science Ltd., Teva Pharmaceuticals USA, Inc., and Tsumura Co. Merck Co., Inc. holds the leading market position with its D-penicillamine drug sales. Valeant Pharmaceuticals International, Inc. follows with patented Trientine Hydrochloride capsules.
Popular Posts
-
คาสิโนออนไลน์อินเดียใดให้เลือกในปี 2565
By mega365nb -
Essential Things To Know About Pickleball Nets
-
Інструкція з обліку військового майна у Збройних Силах України
By Erika Taylor -
Unlock Business Success with Vet1's Top-notch IT Services in Greenville
-
Pinjaman Koperasi: A Roadmap To Financial Stability
